Phase IIa study of BPL-003 in patients with Treatment Resistant Depression
Study overview
The open-label Phase IIa study investigated the safety, efficacy and pharmacokinetics of 10mg of BPL-003 in patients with Treatment Resistant Depression (TRD) who were not taking concomitant antidepressants. TRD was defined as a failure to respond to two or more pharmacological treatments within the current depressive episode.
Key findings
Phase I study of BPL-003 in Healthy Volunteers
Study overview
The double-blind, placebo-controlled, single ascending dose study explored the safety, tolerability, pharmacokinetics and pharmacodynamics of BPL-003 treatment in 44 healthy volunteers. In the study, participants across 7 cohorts were given either a single dose of BPL-003 between 1 mg to 12 mg or a placebo.Â
Key findings
Links to other websites do not imply affiliation or endorsement. 51³Ô¹ÏÍø does not control and is not responsible for their content.